Technology-Assisted Cholesterol Trial in Consumers (TACTiC) - Trial NCT04964544
Access comprehensive clinical trial information for NCT04964544 through Pure Global AI's free database. This Phase 3 trial is sponsored by AstraZeneca and is currently Recruiting. The study focuses on High Cholesterol. Target enrollment is 1220 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
5 mg rosuvastatin calcium with a Web App (combination product)
Interventional
combination product
Sponsor & Location
AstraZeneca
Timeline & Enrollment
Phase 3
Jul 08, 2021
Feb 20, 2023
Primary Outcome
Percentage of participants with an Overall Correct (correct + mitigated) Initial TASS Outcome at the initial self-selection,Percentage of participants with an Overall Correct (correct + mitigated) Final Use Outcome at the final use assessment,Percent change from baseline in verified LDL-C to Visit 2
Summary
The purpose of this AUS is to evaluate the extent to which participants can safely and
 effectively self-select, purchase, and use Crestor OTC 5 mg for a 6-month period according to
 the label.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04964544
Non-Device Trial